How AI Triage in GLP-1 Telehealth Works — and When It Should (and Shouldn't) Replace a Doctor

Artificial intelligence is increasingly embedded in GLP-1 telehealth platforms — from intake screening and symptom triage to dosing recommendations and follow-up scheduling. Some of these applications improve efficiency and patient experience. Others raise serious questions about where the line between helpful automation and inadequate clinical oversight should be drawn.

Where AI Adds Genuine Value in GLP-1 Telehealth

AI-powered tools can enhance GLP-1 telehealth in several legitimate ways:

Pre-screening and intake optimization. AI can efficiently process intake questionnaires to identify patients who clearly don't meet eligibility criteria (BMI below threshold, contraindicated conditions) before they see a provider. This saves clinical time and spares ineligible patients the cost and disappointment of a full consultation. When implemented transparently, this is a win for everyone.

Symptom triage prioritization. When patients report side effects through messaging systems, AI can help prioritize messages by clinical urgency — flagging descriptions that suggest pancreatitis or severe dehydration for immediate provider review while routing routine nausea management questions to a standard response timeline. This can improve response times for the patients who need help most urgently.

Medication interaction screening. AI excels at cross-referencing a patient's medication list against known GLP-1 interaction databases. This automated check can catch interactions that a busy provider might miss, serving as a safety net rather than a replacement for clinical judgment.

Follow-up scheduling and adherence support. Automated reminders for injection days, hydration targets, lab work scheduling, and follow-up appointments improve adherence without requiring clinical staff time.

Where AI Falls Short in GLP-1 Care

Several critical GLP-1 care functions should not be delegated to AI:

Prescribing decisions. The decision to prescribe a GLP-1 medication, select a specific agent, or set a dosing protocol should be made by a licensed clinician who has reviewed the patient's complete medical history, current medications, and individual risk factors. AI can support this decision with data, but the decision itself requires clinical judgment that current AI cannot replicate.

Adverse event assessment. When a patient reports a serious side effect, determining whether it's a medication-related emergency, an unrelated condition, or a manageable side effect requires clinical expertise. AI can flag and prioritize, but the assessment and response must be human.

Mental health evaluation. Screening questionnaires can be AI-administered, but interpreting responses — particularly around suicidal ideation, eating disorders, or complex mood changes — requires human clinical judgment and the ability to ask follow-up questions based on nuance and context.

Complex case management. Patients with multiple comorbidities, medication interactions, or unusual responses to treatment need individualized care plans that account for their unique circumstances. AI protocols are designed for typical cases — complex cases require human adaptability.

Transparency: Does Your Platform Tell You When AI Is Involved?

Perhaps the most important question is whether your platform is transparent about AI involvement in your care. You have the right to know:

• Whether an AI system or a human provider reviewed your intake questionnaire
• Whether dosing recommendations were generated by an algorithm or a clinician
• Whether your follow-up messages are being triaged by AI before reaching a provider
• Whether the "health coach" or "care navigator" you're communicating with is a human, an AI, or a human using AI-generated responses

Platforms that use AI without disclosure are violating the trust that patients place in the provider-patient relationship. You should always know whether you're interacting with a human or a machine.